VIBRA HOSPITAL OF WESTERN MASSACHUSE
1. Target Overview & Investment Thesis
VIBRA HOSPITAL OF WESTERN MASSACHUSE is a 77-bed safety-net/medicaid heavy in HAMPDEN, MA with $24.3M in net patient revenue and a -18.6% operating margin. The hospital serves a payer mix of 12.7% Medicare, 46.0% Medicaid, and 41.3% commercial.
Thesis: Turnaround. Our ML models identify $1.8M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -18.6% to -11.3% (+736bps).
| Net Revenue HCRIS | $24.3M |
| Current EBITDA COMPUTED | $-4.5M |
| Operating Margin COMPUTED | -18.6% |
| Occupancy HCRIS | 73.7% |
| Revenue / Bed COMPUTED | $316K |
| Net-to-Gross HCRIS | 6.7% |
| Distress Probability ML | 51.1% |
2. Market Context & Competitive Position
MA has 99 Medicare-certified hospitals with a median operating margin of -12.2%. The target's margin of -18.6% places it below the state median. Among 48 size-comparable peers (38-154 beds), the median margin is -10.1%. The target's below-peer margin suggests operational improvement opportunity.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (38-154), prioritizing same-state peers. 48 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| VIBRA HOSPITAL OF WESTERN MASS (Target) | MA | 77 | $24.3M | -18.6% |
| BETH ISRAEL DEACONESS - PLYMOU | MA | 150 | $349.1M | 2.6% |
| FAULKNER HOSPITAL | MA | 147 | $316.6M | -7.9% |
| EMERSON HOSPITAL | MA | 111 | $315.1M | -10.1% |
| THE MERCY HOSPITAL | MA | 150 | $276.4M | -12.5% |
| MASSACHUSETTS EYE AND EAR INFI | MA | 41 | $263.9M | -36.1% |
| MILFORD REGIONAL MEDICAL CENTE | MA | 148 | $254.6M | -7.2% |
| COOLEY DICKINSON HOSPITAL | MA | 118 | $233.6M | 2.3% |
| STURDY MEMORIAL HOSPITAL | MA | 125 | $221.7M | -12.2% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $1.8M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $510K | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $486K | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $481K | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $296K | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $16K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-4.5M |
| + RCM Uplift | +$1.8M |
| Pro Forma EBITDA | $-2.7M |
| Current Margin | -18.6% |
| Pro Forma Margin | -11.3% |
| WC Released (1x) | $932K |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-7.0M | $-12.0M | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-7.0M | $-15.4M | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-6.3M | $-11.8M | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-6.3M | $-14.7M | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-7.7M | $-18.7M | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-7.7M | $-23.0M | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
| Medium | Elevated Medicaid exposure (46.0%) | Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims |
| High | Elevated distress probability | Model estimates 51.1% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk |
| Low | Low net-to-gross ratio | Large contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 48 hospitals with 38-154 beds
- Same-state prioritization (n=49)
- Comp margins: P25=-16.8% / P50=-10.1% / P75=2.1%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.